Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-09-18
2003-03-11
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S489000
Reexamination Certificate
active
06531490
ABSTRACT:
TECHNICAL FIELD
The present invention relates to a process for producing compact, spherical agglomerates of inogatran having a narrow size distribution and to inogatran anhydrate.
Inogatran is a low molecular weight thrombin inhibitor exhibiting oral bioavailability, low variability and limited food interaction. The full chemical name of inogatran is: glycine, N-[2-[2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1-piperidinyl]-1-(cyclohexylmethyl)-2 -oxoethyl]-,[2R-[2S]]-and it is disclosed in WO93/11152 (Example 67).
Inogatran i s a slowly crystallising substance showing four polymorphs, of which the one produced by the process of this invention is anhydrous, not hygroscopic and stable.
BACKGROUND ART
A crystalline active drug substance is normally subjected to several processing steps before it is in a form suitable for administration to a human. Such steps are, for example, dry mixing with a filler and a disintegrant, and subsequently adding a binder to form granules; and drying, milling and/or mixing the granules with one or more further additives before a coating is applied or tabletting process employed. A simpler way of producing tablets is by direct compressing where tablets are formed directly after the dry mixing of the active drug substance and the additive(s). However, in order to use a dry compression method the crystalline active drug substance must have good flowability and compressibility. This can be achieved by adding one or more further additives but these further additives are often expensive.
An agglomeration technique has been developed in which crystals of an active drug substance can be directly transformed to microgranules during the crystallization process (see for instance J. Pharm. Sci., Vol 42, No 11, November 1985). By using this the flowability and compressibility of the active drug substance are improved and the active drug substance can be directly compressed to form tablets.
Japanese patent application JP58143832 discloses the preparation of spherical crystals of a crystallisable hydrophobic compound (I), comprising the steps of:
i. dissolving (I) in a mixed solvent comprising 7.0-9.0 parts by weight of water, 2-10 parts by weight of water-immiscible solvent(s) (II), and 10-35 parts by weight of a solvent which is miscible with both water and (II); and,
ii. agitating the solution.
Japanese patent application JP01279869 discloses the preparation of spherical crystals of certain heterocyclic carboxylic acids. The crystals are prepared by dissolving the heterocyclic carboxylic acid in aqueous ammonia solution and adding a water-immiscible organic solvent and an organic solvent which is miscible with both water and the immiscible organic solvent mixture.
Japanese patent application JP04077422 discloses the preparation of spherical granules of clorprenaline hydrochloride by dissolving clorprenaline hydrochloride in a good solvent, dispersing the solution in a poor solvent and evaporating.
The methods disclosed in these Japanese patent applications require substantial stirring, which would result in difficulties if these methods were scaled up. Further, is addition of an emulsifier is necessary in order to prevent droplets coalescing. These prior art methods are applicable only for fast crystallizing substances.
When these agglomeration techniques are applied to substances having slow crystallization kinetics a paste-like precipitate with unsuitable properties is formed. Also, in large scale production difficulties would be met in obtaining the extremely high stirring rates that would be required with applications based on these techniques.
Document WO 97/49681 discloses a process for isolating crystalline fluvastatin sodium form B which comprises: (a) dissolving fluvastatin sodium in a first organic solvent or a mixture of a first organic solvent and water; (b) adding water if required and a polar precipitating organic solvent so as to obtain crystallization of fluvastatin sodium form B, optionally following seeding with crystalline fluvastatin sodium form B; and (c) isolating and drying the crystalline fluvastatin sodium form B thus obtained. This process results in needlelike crystals of fluvastatin sodium form B.
None of the methods mentioned above are suitable for the production of compact, spherical aggregates with narrow size distribution which would allow subsequent use of a coating process.
DISCLOSURE OF THE INVENTION
A process has now been found by which compact, spherical agglomerates of inogatran with a narrow size distribution (from 30 to 110 &mgr;m, especially from 30 to 100 &mgr;m) can be formed.
The present invention provides a process for producing spherical agglomerates of inogatran (for example inogatran anhydrate) comprising the consecutive steps of:
a) dissolving inogatran in one of its instable, hygroscopic, hydrate forms (for example inogatran monohydrate) in a mixture of a good solvent for inogatran (L1) and a poor solvent for inogatran (L3) to form a concentrated solution,
b) optionally filtering the solution,
c) concentrating the concentrated solution further,
d) adding a non-solvent for inogatran (L2) to obtain supersaturation, and
e) adding further (L2) when nucleation has started.
Steps (a) to (e) can be followed by measures to isolate the product.
According to the process of the present invention there is no specific demand for stirring and the process can be easily scaled up. The spherical agglomerates of inogatran produced by the process of this invention require no additives for improving their flowability or compressibility prior to tabletting by a dry compression method.
In the present specification a good solvent is defined as a liquid in which inogatran is very soluble (that is, more than about 0.03 g inogatran/g solvent); a poor solvent is a liquid where inogatran is sparingly to very slightly soluble (that is, about 0.0001-0.03 g inogatran/g solvent); and a non-solvent where inogatran is practically insoluble (that is, less than about 0.0001 g inogatran/g solvent).
In one aspect of the invention the mixture of (L1) and (L3) has a ratio in the range 0.97-0.90:0.03-0.10 (w/w).
In a further aspect of the invention the amount of (L1), (L2) and (L3) per weight of inogatran is in the range from 7 to 15 ml per g inogatran.
In a still further aspect of the invention the ratio of [(L1)+(L3)]:L2) is preferably from 1:1.5 to 1:4 (v/v).
In step (a) a concentrated solution is a solution having, for example, more than 10 g inogatran per 100 ml of solvent (such as more than 20 g inogatran per 100 ml of solvent).
As an optional step between steps (b) and (c) a further step can be added wherein the equipment and the filter plate is washed with (L1) in order to minimize losses of inogatran.
In another aspect of the invention an appropriate amount of inogatran is dissolved in a mixture of L1 and L3 to form a highly concentrated solution. Optionally, the solution is filtered. Non-solvent L2 is then added slowly to the highly concentrated solution while stirring slowly to allow (as visually judged by the first appearance of opalescence) the formation of small quasi-emulsion droplets of inogatran/L1/L3 in the dispersion medium L2. The solution is preferably seeded to start nucleation and, when nucleation has occurred, more L2 is added. The crystallization is then allowed to proceed until equilibrium has occured. Preferably the product obtained is filtered and dried after equilibrium has been achieved.
The size of the spherical agglomerates of inogatran produced by the process is primarily dependent on the size of the quasi-emulsion droplets and stirring has only a marginal effect on the size of the quasi-emulsion droplets.
Any type of solvent can be used in the process of the invention. Suitable solvents for inogatran are: L1=ethanol; L2=ethyl acetate; L3=water, but other choices are possible.
The size of the quasi-emulsion droplets (and thus the size of the agglomerates produced) can be controlled by temperat
Horvath Karol
Lindqvist Bo
AstraZeneca AB
Page Thurman K.
Pulliam Amy E
White & Case LLP
LandOfFree
Production of agglomerates of inogatran and the compound... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of agglomerates of inogatran and the compound..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of agglomerates of inogatran and the compound... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3055798